NO20082510L - En fremgangsmate for konsentrasjon av et polypeptid - Google Patents

En fremgangsmate for konsentrasjon av et polypeptid

Info

Publication number
NO20082510L
NO20082510L NO20082510A NO20082510A NO20082510L NO 20082510 L NO20082510 L NO 20082510L NO 20082510 A NO20082510 A NO 20082510A NO 20082510 A NO20082510 A NO 20082510A NO 20082510 L NO20082510 L NO 20082510L
Authority
NO
Norway
Prior art keywords
polypeptide
concentration
composition
concentrating
interest
Prior art date
Application number
NO20082510A
Other languages
English (en)
Inventor
Stefan Nilsson
Original Assignee
Zymenex As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymenex As filed Critical Zymenex As
Publication of NO20082510L publication Critical patent/NO20082510L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01061—Hydroxymethylbilane synthase (2.5.1.61)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01024—Alpha-mannosidase (3.2.1.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01046—Galactosylceramidase (3.2.1.46)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Water Supply & Treatment (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Foreliggende oppfinnelsen omfatter en fremgangsmåte for konsentrering av en sammensetning omfattende et polypeptid av interesse og anvendelsen av en slik konsentrert sammensetning for behandlingen av sykdommer hos pattedyr, især ved subkutan injeksjon.
NO20082510A 2006-04-04 2008-05-30 En fremgangsmate for konsentrasjon av et polypeptid NO20082510L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200600488 2006-04-04
DKPA200600922 2006-07-05
PCT/DK2007/000177 WO2007112757A2 (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide

Publications (1)

Publication Number Publication Date
NO20082510L true NO20082510L (no) 2008-10-31

Family

ID=38472949

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20211305A NO347673B1 (no) 2006-04-04 2007-04-04 En sammensetning som omfatter konsentrert polypeptide og bruk derav.
NO20082510A NO20082510L (no) 2006-04-04 2008-05-30 En fremgangsmate for konsentrasjon av et polypeptid
NO20084776A NO346368B1 (no) 2006-04-04 2008-11-12 En fremgangsmåte for konsentrasjon av alfa-mannosidase.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20211305A NO347673B1 (no) 2006-04-04 2007-04-04 En sammensetning som omfatter konsentrert polypeptide og bruk derav.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20084776A NO346368B1 (no) 2006-04-04 2008-11-12 En fremgangsmåte for konsentrasjon av alfa-mannosidase.

Country Status (20)

Country Link
US (6) US20090246187A1 (no)
EP (4) EP2628746B1 (no)
JP (6) JP2009532394A (no)
KR (3) KR20140057678A (no)
CN (1) CN105233276A (no)
AU (2) AU2007234195B2 (no)
BR (1) BRPI0709737A2 (no)
CA (3) CA2644642C (no)
DK (1) DK2628746T3 (no)
ES (3) ES2744499T3 (no)
HU (1) HUE042402T2 (no)
IL (4) IL194267A (no)
MX (1) MX2008012748A (no)
NO (3) NO347673B1 (no)
NZ (7) NZ607595A (no)
PL (3) PL2100898T3 (no)
PT (1) PT2628746T (no)
SI (1) SI2628746T1 (no)
WO (1) WO2007112757A2 (no)
ZA (2) ZA200805346B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2554883C (en) 2004-01-30 2013-10-01 Zymenex A/S Production and purification of recombinant arylsulfatase a
JP2009532394A (ja) * 2006-04-04 2009-09-10 シャイア ファーマシューティカルズ アイルランド リミテッド ポリペプチドの濃縮方法
PL2538968T3 (pl) 2010-02-24 2018-04-30 Chiesi Farmaceutici S.P.A. Sposób wytwarzania i oczyszczania rekombinowanej lizosomalnej alfamannozydazy
PT3626258T (pt) 2010-06-25 2021-10-19 Shire Human Genetic Therapies Métodos e composições para fornecimento ao snc de iduronato-2-sulfatase
US9320711B2 (en) 2010-06-25 2016-04-26 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of heparan N-sulfatase
RU2626514C2 (ru) 2010-06-25 2017-07-28 Шир Хьюман Дженетик Терапис, Инк. Доставка к цнс лечебных агентов
PL3626257T3 (pl) * 2010-06-25 2022-03-28 Shire Human Genetic Therapies, Inc. Sposoby i kompozycje do dostarczania arylosulfatazy a do oun
EP2729566B1 (en) 2011-07-08 2017-03-15 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
EP2793922B1 (en) 2011-12-23 2019-10-30 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
AU2013347260B2 (en) * 2012-11-13 2016-07-28 Chiesi Farmaceutici S.P.A. Purification of recombinant human galactocerebroside beta-galactosidase (rhGALC)
MX2015007494A (es) * 2012-12-11 2015-12-15 Centogene Ag Metodo para diagnosticar leucodistrofia metacromatica.
ES2768261T3 (es) 2013-01-09 2020-06-22 Shire Human Genetic Therapies Métodos para la purificación se arilsulfatasa A
EP2968498A4 (en) 2013-03-15 2016-09-07 Biogen Ma Inc PREPARATIONS CONTAINING FACTOR IX POLYPEPTIDE
EP3123090A4 (en) * 2014-03-24 2017-12-13 Bioverativ Therapeutics Inc. Lyophilized factor ix formulations
JP6957738B2 (ja) * 2017-08-31 2021-11-02 グリーン・クロス・コーポレイションＧｒｅｅｎ Ｃｒｏｓｓ Ｃｏｒｐ． スルファターゼタンパク質を精製する方法
KR102290596B1 (ko) * 2020-09-10 2021-08-19 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 주사용 조성물 및 이의 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2041280A1 (en) 1990-05-10 1991-11-11 Yosuke Sawada Arylsulfatase
NO960163D0 (no) * 1996-01-15 1996-01-15 Thomas Berg Mutasjonsdeteksjon av bovin
CA2319096C (en) 1998-01-27 2007-07-03 Hemebiotech A/S Method for treating acute intermittent porphyria (aip) and other porphyric diseases
ES2421736T3 (es) * 1998-06-09 2013-09-05 Csl Behring Ag Procedimiento para la preparación de inmunoglobulinas para administración intravenosa y otros productos inmunoglobulínicos
CA2330170C (en) * 1998-06-09 2010-11-02 Statens Serum Institut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
US6537777B1 (en) 1998-07-27 2003-03-25 Hemebiotech A/S Human porphobilinogen deaminase sequences
AUPQ026799A0 (en) * 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
AU774603B2 (en) * 1999-07-27 2004-07-01 Zymenex A/S Production of rhPBGD and new therapeutic methods for treating patients with acute intermittent porphyria (AIP) and other porphyric diseases
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
EP1409695A2 (en) 2000-11-15 2004-04-21 Genzyme Corporation Expression system for recombinant proteins
WO2002099092A2 (en) 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human lysosomal alpha-mannosidase
AU2002317700A1 (en) * 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
EP1402014A1 (en) * 2001-06-29 2004-03-31 Hemebiotech A/S A process for purification of recombinant porphobilinogen deaminase
US7232670B2 (en) * 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
AU2003222568B2 (en) 2002-01-11 2009-05-07 Bioasis Technologies, Inc. Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
AU2003212912A1 (en) * 2002-02-04 2003-09-02 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
CH694697A5 (de) 2004-01-29 2005-06-15 Koelbl Engineering Und Consult Gummimehl-enthaltende Elastomerlegierungen.
CA2554883C (en) * 2004-01-30 2013-10-01 Zymenex A/S Production and purification of recombinant arylsulfatase a
DK1740204T3 (en) 2004-04-01 2018-05-22 Chiesi Farm Spa MEDICAL USE OF ALFA MANNOSIDASE
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JP2009532394A (ja) * 2006-04-04 2009-09-10 シャイア ファーマシューティカルズ アイルランド リミテッド ポリペプチドの濃縮方法

Also Published As

Publication number Publication date
ES2744499T3 (es) 2020-02-25
NZ607595A (en) 2014-10-31
JP2009273469A (ja) 2009-11-26
IL241654B (en) 2019-02-28
US9713634B2 (en) 2017-07-25
NZ597548A (en) 2013-08-30
AU2007234195B2 (en) 2013-02-07
US20160193304A1 (en) 2016-07-07
AU2007234195A1 (en) 2007-10-11
US20140314735A1 (en) 2014-10-23
EP2628746A3 (en) 2014-03-19
IL241654A0 (en) 2015-11-30
AU2008229659B2 (en) 2013-01-31
AU2008229659A1 (en) 2008-10-23
KR20090018894A (ko) 2009-02-24
CA2632528A1 (en) 2007-10-11
KR20140057678A (ko) 2014-05-13
JP2016104000A (ja) 2016-06-09
EP2631242B1 (en) 2022-08-03
IL211905A0 (en) 2011-05-31
EP2631242A2 (en) 2013-08-28
EP2100898B1 (en) 2019-06-19
NZ582045A (en) 2011-07-29
KR20150103339A (ko) 2015-09-09
EP2628746B1 (en) 2019-01-09
ZA200805346B (en) 2018-11-28
SI2628746T1 (sl) 2019-04-30
CA2644642A1 (en) 2007-10-11
NO20084776L (no) 2008-10-31
JP2014051503A (ja) 2014-03-20
CA2882501C (en) 2021-09-07
HUE042402T2 (hu) 2019-06-28
US20180289777A1 (en) 2018-10-11
PL2628746T3 (pl) 2019-07-31
IL194267A0 (en) 2011-08-01
WO2007112757A2 (en) 2007-10-11
NZ568728A (en) 2011-09-30
CA2882501A1 (en) 2007-10-11
NZ623123A (en) 2015-04-24
EP2100898A1 (en) 2009-09-16
NZ588903A (en) 2012-08-31
CA2644642C (en) 2016-01-26
EP2631242A3 (en) 2013-10-02
US20090246187A1 (en) 2009-10-01
PT2628746T (pt) 2019-04-23
BRPI0709737A2 (pt) 2011-07-26
JP5878152B2 (ja) 2016-03-08
EP2004672A2 (en) 2008-12-24
PL2100898T3 (pl) 2019-11-29
ES2928096T3 (es) 2022-11-15
JP2014058521A (ja) 2014-04-03
KR101504969B1 (ko) 2015-03-24
US20120076767A1 (en) 2012-03-29
ES2713488T3 (es) 2019-05-22
IL194267A (en) 2015-10-29
IL235982A0 (en) 2015-01-29
DK2628746T3 (en) 2019-04-01
MX2008012748A (es) 2009-01-07
US8809055B2 (en) 2014-08-19
NO346368B1 (no) 2022-06-27
NO347673B1 (no) 2024-02-19
EP2004672B1 (en) 2015-08-19
NO20211305A1 (no) 2008-10-31
EP2628746A2 (en) 2013-08-21
JP5384232B2 (ja) 2014-01-08
ZA200809540B (en) 2019-09-25
CA2632528C (en) 2022-07-12
JP2009532394A (ja) 2009-09-10
JP2013236633A (ja) 2013-11-28
CN105233276A (zh) 2016-01-13
NZ571610A (en) 2011-07-29
WO2007112757A3 (en) 2008-02-28
PL2631242T3 (pl) 2023-03-20
US20170202927A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
NO20082510L (no) En fremgangsmate for konsentrasjon av et polypeptid
MX2021012669A (es) Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5- il)-piridin-3-il)metoxi)benzaldehido.
EA201171220A1 (ru) Мутанты fgf21 и их применение
EA201690946A1 (ru) Мутанты fgf21 и их применение
EA201590525A1 (ru) Слитые белки для лечения метаболического синдрома
EA201490695A1 (ru) Слитые белки для лечения нарушений метаболизма
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
EA201390739A1 (ru) Способ лечения fgf21-ассоциированных расстройств
EA200971077A1 (ru) Гетероциклические модуляторы киназы
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
EA201990619A1 (ru) Fgf21 мутанты и их применение
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
MX2009002999A (es) Analogos de insulina resistentes a proteasa.
RS53236B (en) BETA-AMYLOIDOSIS PEPTIDES
NZ597692A (en) Anti-IGF antibodies
NO20054958L (no) Substitulerte aminokarboksylsyrer
EA201491155A1 (ru) Новые мутантные про-нрф и их применение для получения бета-нрф
AR088737A1 (es) Familia de toxinas inhibidoras de insectos activa contra insectos hemipteros y/o lepidopteros
EA200700391A1 (ru) Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1
CY1110488T1 (el) Μεθοδος για την παρασκευη καρβοξυ-τερματικων αμιδουχων πεπτιδιων
EA201290069A1 (ru) Модифицированные полипептиды фактора ix и их применения
EA201170879A1 (ru) Полипептиды с ксиланазной активностью
EA201100071A1 (ru) Новые композиции и способы
IL189452A0 (en) Therapy with cd4 binding peptides and radiation
TW200716132A (en) Novel chemical compounds

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED, JP

CREP Change of representative

Representative=s name: AWA NORWAY AS, C/O REGUS BUSINESS CENTER AKER

FC2A Withdrawal, rejection or dismissal of laid open patent application